comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 09:58:11 - browse：83

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Hospital chaplains balance Covid safety with patients’ spiritual needs

WSS

Advances in CAR

Hospital chaplains balance Covid safety with patients’ spiritual needs

Crinetics acromegaly drug succeeds in late

How to protect patients from sexual assault

Life science postdocs should get big pay hike, NIH panel says

Ascension's ugly legal battle over care for poor patients in Texas

leisure time

comprehensive

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Boston Scientific acquires urology company Axonics for $3.7 billion

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How generative AI is inspiring dreams of a health data revolution

Continuity nursing helped my family in our darkest PICU moments

Snackable artificial intelligence, expert AI, and the pharma industry

Heart attack and stroke risk calculators need revising

Covid hospitalizations on the rise, Humana says

At least 13 dead in Texas as scorching temps continue

A preacher's new calling: Diversifying neuroscience research

entertainment

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Medicare Advantage coverage denials need scrutiny, senators say

What drug price negotiations mean for Medicare Part D

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Stem cell treatment guidelines are released by FDA

How to protect patients from sexual assault

hotspot

knowledge

knowledge

Wikipedia